| PUBLICATIONS (Ranked by impact factor of the journal) | LABORATORY RESEARCH New Therapy Targeting Differential Androgen Receptor Signaling in Prostate Cancer Stem/Progenitor vs Non-Stem/Progenitor cells Scientists found that targeting prostate cancer (PCa) non-stem/progenitor cells with androgen receptor (AR) degradation enhancer ASC-J9® and targeting PCa stem/progenitor cells with 5-AZA and γ-TT resulted in significant suppression of the PCa at the castration resistant stage. [J Mol Cell Biol] Abstract Anisamide-Targeted Cyclodextrin Nanoparticles for siRNA Delivery to Prostate Tumors in Mice Researchers synthesized and compared a hepta-guanidino-β-cyclodextrin, its hepta-PEG conjugate, and the corresponding anisamide-terminated PEG conjugate as delivery vectors for siRNA to prostate cancer cells and tumors in vivo. [Biomaterials] Abstract c-Myc Expression and MEK1 Induced Erk2 Nuclear Localization are Required for TGF-Beta Induced Epithelial-Mesenchymal Transition and Invasion in Prostate Cancer Investigators showed that expression of the transcription factor c-myc, which is phosphorlyated by Erk2, is required for epithelial to mesenchymal transitions. [Carcinogenesis] Abstract Distinct Roles of AKT Isoforms in Regulating β1-Integrin Activity, Migration and Invasion in Prostate Cancer Validation experiments investigating all three AKT isoforms demonstrated that both AKT1 and AKT2 function as negative regulators of cell migration and invasion in PC3 prostate cancer cells. [Mol Biol Cell] Abstract Inhibition of Ca2+– Activated Cl− Channel ANO1/TMEM16A Expression Suppresses Tumor Growth and Invasiveness in Human Prostate Carcinoma Scientists provided evidence that upregulation of Ca2+– activated Cl− channel ANO1 is involved in the proliferation, progression and pathogenesis of metastatic prostate cancer. [Cancer Lett] Abstract Silibinin Inhibits Wnt/β-Catenin Signaling by Suppressing Wnt Co-Receptor LRP6 Expression in Human Prostate and Breast Cancer Cells Researchers found that silibinin was able to suppress endogenous lipoprotein receptor-related protein-6 (LRP6) expression and phosphorylation and block Wnt/β-catenin signaling in prostate cancer PC-3 and DU-145 cells and breast cancer MDA-MB-231 and T-47D cells. [Cell Signal] Abstract Anti-Proliferative Effect of 23,24-Dihydrocucurbitacin F on Human Prostate Cancer Cells through Induction of Actin Aggregation and Cofilin-Actin Rod Formation Investigators explored the level and mechanisms of 23,24-dihydrocucurbitacin F toxicity on human prostate cancer cell lines. [Cancer Chemother Pharmacol] Abstract Fractionated Radiation Alters Oncomir and Tumor Suppressor miRNAs in Human Prostate Cancer Cells To understand the role of miRNA in regulation of radiation-induced gene expression, investigators analyzed miRNA expression in LNCaP, PC3 and DU145 prostate cancer cells treated with single-dose radiation and fractionated radiation by microarray. [Radiat Res] Abstract Antitumor Effects of the Novel Quinazolinone MJ-33: Inhibition of Metastasis through the Mitogen-Activated Protein Kinase, AKT, NF-κB and Activator Protein-1 Signaling Pathways in DU145 Human Prostate Cancer Cells Scientists investigated the anti-metastatic activity of MJ-33 and the signaling pathway of MJ-33 in human prostate cells. [Int J Oncol] Abstract CLINICAL RESEARCH Prostate Biopsy in Response to a Change in Nadir Prostate Specific Antigen of 0.4 ng/ ml after Treatment with 5α-Reductase Inhibitors Markedly Enhances the Detection Rate of Prostate Cancer Researchers examined the effect of 5α-reductase inhibitor therapy on prostate cancer detection in men with persistently increased or fluctuating prostate specific antigen and prior negative prostate cancer biopsy. [J Urol] Abstract A Phase I Study of a Chimeric Monoclonal Antibody Against Interleukin-6, Siltuximab, Combined with Docetaxel in Patients with Metastatic Castration-Resistant Prostate Cancer Scientists assessed the safety and tolerability of siltuximab in combination with docetaxel, the pharmacokinetics of docetaxel alone and with siltuximab, and the efficacy and pharmacodynamics of siltuximab plus docetaxel. [Invest New Drugs] Abstract |
| JOB OPPORTUNITIES | Quality Control Operations Coordinator (STEMCELL Technologies, Inc.) Research Associate – Chemistry (STEMCELL Technologies, Inc.) Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.) Research Technologist – Research and Development (STEMCELL Technologies, Inc.) Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.) Research Technologist – Media Development (STEMCELL Technologies, Inc.) Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.) Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.) Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.) Scientist – hPSC Bioengineering (STEMCELL Technologies, Inc.) Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.) Postdoctoral Position – Cancer Genomics (University of California) Postdoctoral Position – Endocrinology of Prostate Cancer (Baylor College of Medicine) Postdoctoral Position – Molecular Biology and Genomics (University Hospital Zurich) Postdoctoral Position – Prostate Cancer Research (University of Texas Southwestern Medical Center) Postdoctoral Position – Prostate Cancer (BC Cancer Agency) Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost. |
|
|
|